RIM
IOVA icon

RS Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

RS Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$17.9M Sell
2,214,585
-479,913
-18% -$3.01M 0.18% 192
2016
Q1 		$13.7M Buy
2,694,498
+41,638
+2% +$228K 0.14% 218
2015
Q4 		$20.5M Buy
2,652,860
+306,490
+13% +$2.13M 0.18% 177
2015
Q3 		$13.5M Buy
2,346,370
+670,660
+40% +$5.22M 0.12% 212
2015
Q2 		$15.4M Buy
+1,675,710
New +$18.7M 0.13% 216

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

RS Investment Management's IOVA Position: Q2 2016 in Review

RS Investment Management reduced its Iovance Biotherapeutics (IOVA) stake by 18% in Q2 2016, selling an estimated $3.01M and leaving 2,214,585 shares worth $17.9M. The position accounts for 0.18% of the portfolio, ranked #192.

RS Investment Management first reported a position in IOVA in Q2 2015 and has held it in 5 quarters since. The position peaked at $20.5M in Q4 2015. 82 funds tracked by Wall St. Rank hold IOVA as of Q2 2016.

  • RS Investment Management held 2,214,585 shares of Iovance Biotherapeutics worth $17.9M as of Q2 2016.
  • RS Investment Management sold 479,913 Iovance Biotherapeutics shares in Q2 2016, an estimated $3.01M.
  • Iovance Biotherapeutics made up 0.18% of RS Investment Management's portfolio in Q2 2016, its #192 holding.
  • RS Investment Management first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 5 quarters since.
  • RS Investment Management's Iovance Biotherapeutics position peaked at $20.5M in Q4 2015.
  • 82 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.